Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $61.07 (market cap $44.49B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 7.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 5,681,789). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and JPMorgan Nasdaq Equity Premium Income ETF for 65 Days on average.
| IOVA | JEPQ | |
|---|---|---|
Market Cap | $6.04B | $44.49B |
Volume | 14,805,993 | 5,681,789 |
Sector | Health | Income / Options Overlay |
52-Week High | $14.82 | $61.46 |
52-Week Low | $1.81 | $53.77 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JEPQ trades at $61.03, down 0.39% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong income generation through its covered-call strategy, with recent dividends ranging from $0.57 to $0.70 per share. Financial media coverage highlights JEPQ's 11% estimated annualized yield and suitability for retirement income, though analysts note the trade-off between high current income and limited price appreciation potential.
JEPQ offers exceptional current income for investors seeking monthly cash flow, with its covered-call strategy performing well in volatile markets. However, the ETF faces risks from market volatility dependence and potential principal erosion if yield chasing outweighs total return considerations. Institutional interest remains strong, with Envestnet increasing its position by 8.2% recently.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
